Replimune Group, Inc.
$2.07
▲
10.51%
2026-04-21 09:07:00
www.replimune.com
NMS: REPL
Explore Replimune Group, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$170.93 M
Current Price
$2.07
52W High / Low
$13.24 / $1.5
Stock P/E
—
Book Value
$2.64
Dividend Yield
—
ROCE
-53.14%
ROE
-90.88%
Face Value
—
EPS
$-3.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
479
Beta
0.74
Debt / Equity
36.26
Current Ratio
5.6
Quick Ratio
7.95
Forward P/E
-2.37
Price / Sales
—
Enterprise Value
$200.25 M
EV / EBITDA
-0.63
EV / Revenue
—
Rating
Buy
Target Price
$12.86
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 2. | Aspire Biopharma Holdings, Inc. | $0.26 | — | $1.36 M | — | 308.11% | 618.48% | $35 / $0.22 | $-1.8 |
| 3. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 4. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 5. | Celcuity Inc. | $120.09 | — | $5.8 B | — | -40.76% | -1.64% | $127.34 / $9.5 | $2.08 |
| 6. | Outlook Therapeutics, Inc. | $0.37 | — | $38.71 M | — | 246.27% | 118.61% | $3.39 / $0.16 | $-0.6 |
| 7. | Acrivon Therapeutics, Inc. | $1.86 | — | $68.97 M | — | -73.75% | -53.86% | $3.56 / $1.05 | $3.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -71.53 M | -83.91 M | -90 M | -78.78 M | -65.64 M | — |
| Net Profit | -70.93 M | -83.1 M | -86.69 M | -74.13 M | -66.34 M | — |
| EPS in Rs | -0.86 | -1.01 | -1.05 | -0.9 | -0.8 | -0.68 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -259.85 M | -232.85 M | -174.17 M | -115.14 M |
| Net Profit | -247.3 M | -215.79 M | -174.28 M | -118.04 M |
| EPS in Rs | -2.99 | -2.61 | -2.11 | -1.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 551.33 M | 487.72 M | 646.59 M | 461.19 M |
| Total Liabilities | 135.49 M | 113.21 M | 91.3 M | 49.96 M |
| Equity | 415.84 M | 374.51 M | 555.29 M | 411.23 M |
| Current Assets | 495.88 M | 433.67 M | 592.6 M | 403.98 M |
| Current Liabilities | 62.36 M | 40.44 M | 33.83 M | 20.76 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -192.25 M | -185.47 M | -128.05 M | -82.18 M |
| Investing CF | -23.8 M | 97.2 M | -142.5 M | -1.81 M |
| Financing CF | 252.4 M | 16.28 M | 311.3 M | 6.6 M |
| Free CF | -198.94 M | -191.13 M | -130.32 M | -84.52 M |
| Capex | -6.69 M | -5.66 M | -2.27 M | -2.34 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -14.6% | -23.82% | -47.65% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.